Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action

Amerikanou, Charalampia; Papada, Efstathia; Gioxari, Aristea; Smyrnioudis, Ilias; Kleftaki, Stamatia-Angeliki; Valsamidou, Evdokia; Bruns, Victoria; Banerjee, Rajarshi; Trivella, Maria Giovanna; Milić, Nataša; Medić-Stojanoska, Milica; Gastaldelli, Amalia; Kannt, Aimo; Dedoussis, George; Kaliora, Andriana C.

doi:10.1016/j.phrs.2021.105753

Cited by 26 publications

(16 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increasing evidence has highlighted miRNAs as the indispensable regulator in IBD development 13 , 14 , 15 miR-146b has been previously reported closed related to IBD development [ 23 , 24 ]. Deng et al [23] have identified miR-146b gradually increased during mucosal regeneration in a murine colitis model.…”

Section: Discussionmentioning

confidence: 99%

“…MicroRNAs have been identified as a type of small molecular RNA, which play an indispensable role in modulating IBD progression. According to previous evidence, MicroRNAs such as microRNA-155 [13] , miR-142-3p[14] and MiR-223[15] affected inflammation in IBD. More specifically, Guo et al [16] disclosed that miRNA-29c-3p could deteriorate the inflammation level in Ulcerative Colitis through mediating leukemia inhibitory factor, Li et al.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

miR-146b suppresses LPS-induced M1 macrophage polarization via inhibiting the FGL2-activated NF-κB/MAPK signaling pathway in inflammatory bowel disease

Pan

Wang

Fan

2022

Clinics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

miR-146b suppresses LPS-induced M1 macrophage polarization via inhibiting the FGL2-activated NF-κB/MAPK signaling pathway in inflammatory bowel disease

Pan

Wang

Fan

2022

Clinics

View full text Add to dashboard Cite

“…Future research on the impacts of miRNAs is needed in order to better understand their functions and reveal the potential beneficial effects of their actions. MicroRNAs are a promising target for the development of therapies for many diseases, including NAFLD [67,143].…”

Section: Pharmacotherapymentioning

confidence: 99%

What’s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)

Kosmalski

Frankowski

Ziółkowska

et al. 2023

JCM

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a serious health problem due to its high incidence and consequences. In view of the existing controversies, new therapeutic options for NAFLD are still being sought. Therefore, the aim of our review was to evaluate the recently published studies on the treatment of NAFLD patients. We searched for articles in the PubMed database using appropriate terms, including “non-alcoholic fatty liver disease”, “nonalcoholic fatty liver disease”, “NAFLD”, “diet”, “treatment”, “physical activity”, “supplementation”, “surgery”, “overture” and “guidelines”. One hundred forty-eight randomized clinical trials published from January 2020 to November 2022 were used for the final analysis. The results show significant benefits of NAFLD therapy associated with the use of not only the Mediterranean but also other types of diet (including low-calorie ketogenic, high-protein, anti-inflammatory and whole-grain diets), as well as enrichment with selected food products or supplements. Significant benefits in this group of patients are also associated with moderate aerobic physical training. The available therapeutic options indicate, above all, the usefulness of drugs related to weight reduction, as well as the reduction in insulin resistance or lipids level and drugs with anti-inflammatory or antioxidant properties. The usefulness of therapy with dulaglutide and the combination of tofogliflozin with pioglitazone should be emphasized. Based on the results of the latest research, the authors of this article suggest a revision of the therapeutic recommendations for NAFLD patients.

show abstract

“…[59][60][61][62] Although the pathogenesis of NAFLD is not entirely understood, it is believed to respond to treatments other than lifestyle modifications when the latter is not useful, 63 and miRNAs have proven to be an essential regulator of inflammation in NAFLD. 64,65 With technologies such as miRNA microarrays and miRNA sequencing, the circulating levels of unregulated miRNAs can be detected in body fluids and tissues that are thought to have prognostic significance. 66,67 Currently, miRNA sensors and decoy libraries are being established to assess miRNA activities and inhibit their physiological effects.…”

Section: Use Of Mrna As Therapeuticsmentioning

confidence: 99%

Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review

Kan Changez,

Mubeen,

Zehra

et al. 2023

J Int Med Res

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a prevalent liver condition that affects people who do not overconsume alcohol. Uncertainties exist over how microRNAs (miRNAs) in the blood and liver relate to NAFLD. The aim of this narrative review was to investigate the role of miRNAs in the onset and progression of non-alcoholic steatohepatitis (NASH) from NAFLD, and explore their potential as diagnostic tools and treatment targets for NAFLD patients. Liver miRNA-34a levels were found to accurately represent the degree of liver damage, with lower levels suggesting more damage. In patients with NAFLD and severe liver fibrosis, higher levels of miRNA-193a-5p and miRNA-378d were found. Moreover, miRNA-34a, miRNA-122, and miRNA-192 levels might aid in differentiating NASH from NAFLD. Similar to this, miRNA-21 and miRNA-27 levels in rats were able to distinguish between steatosis and steatohepatitis. High-fat diets enhanced the expression of 15 distinct miRNAs in rats, and there were substantial differences in the miRNA expression patterns between obese and lean people. The results from the present review imply that miRNA microarrays and sequencing may be helpful diagnostic tools, and miRNAs may be a possible treatment target for patients with NAFLD.

show abstract

Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action

Cited by 26 publications

References 72 publications

miR-146b suppresses LPS-induced M1 macrophage polarization via inhibiting the FGL2-activated NF-κB/MAPK signaling pathway in inflammatory bowel disease

miR-146b suppresses LPS-induced M1 macrophage polarization via inhibiting the FGL2-activated NF-κB/MAPK signaling pathway in inflammatory bowel disease

What’s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)

Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review

Contact Info

Product

Resources

About